Corrigendum To: PIWIL1 Promotes Malignant Progression of Papillary Thyroid Carcinoma by Inducing EVA1A Expression.

IF 2.3 4区医学 Q3 ONCOLOGY

Current cancer drug targets Pub Date : 2025-01-01 DOI:10.2174/156800962503241107164731

Lianyong Liu, Fengying Wu, Xiaoying Zhang, Xiangqi Li

引用次数: 0

Abstract

In the article titled "PIWIL1 Promotes Malignant Progression of Papillary Thyroid Carcinoma by Inducing EVA1A Expression" published in Current Cancer Drug Targets, Volume 24, No. 2, 2024, pp. 192-203, the authors have identified errors in Figures 6 (E, F) and 7 (E, F). They request corrections to these figures to ensure accuracy in the representation of their findings. We regret the error and apologize to readers. The original article can be found online at: https://www.eurekaselect.com/article/132737.

查看原文本刊更多论文

Corrigendum To：PIWIL1通过诱导EVA1A表达促进甲状腺乳头状癌恶性进展

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current cancer drug targets 医学-肿瘤学

CiteScore

5.40

自引率

0.00%

发文量

105

审稿时长

1 months

期刊介绍： Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes. Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer. As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.